E2696: ECOG E2696 Trial
In hdbayes: Bayesian Analysis of Generalized Linear Models with Historical Data
E2696 R Documentation
ECOG E2696 Trial
Description
A data set from the ECOG E2696 trial comparing the combination of the GM2-KLH/QS-21 (GMK) vaccine
and high-dose interferon alfa-2b (IFN) therapy with the GMK vaccine alone in resected high-risk
melanoma patients. The study results were described in Kirkwood et al. (2001) doi:10.1200/JCO.2001.19.5.1430.
This data set only includes patients without nodal metastasis.
Usage
E2696
Format
A data frame with 105 rows and 6 variables:
- failtime
relapse-free survival (RFS) times (in months)
- failind
relapse indicator, 0 = right censored, 1 = relapse
- treatment
treatment indicator, 0 = GMK, 1 = GMK and IFN
- sex
gender indicator, 0 = male, 1 = female
- age
patient age in years
- perform
ECOG performance status indicator, 0 = fully active patient, able to
carry on all pre-disease performance without restriction,
1 = restricted in physically strenuous activity, but are ambulatory
and able to carry out work of a light or sedentary nature
References
Kirkwood, J. M., Ibrahim, J., Lawson, D. H., Atkins, M. B., Agarwala, S. S., Collins, K., Mascari, R., Morrissey, D. M., and Chapman, P. B. (2001). High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: Results of the multicenter eastern cooperative oncology group phase II trial E2696. Journal of Clinical Oncology, 19(5), 1430–1436.
hdbayes documentation built on Sept. 11, 2024, 5:34 p.m.
R Package Documentation
Browse R Packages
We want your feedback!
Note that we can't provide technical support on individual packages. You should contact the package authors for that.
| E2696 | R Documentation |
ECOG E2696 Trial
Description
A data set from the ECOG E2696 trial comparing the combination of the GM2-KLH/QS-21 (GMK) vaccine and high-dose interferon alfa-2b (IFN) therapy with the GMK vaccine alone in resected high-risk melanoma patients. The study results were described in Kirkwood et al. (2001) doi:10.1200/JCO.2001.19.5.1430. This data set only includes patients without nodal metastasis.
Usage
E2696
Format
A data frame with 105 rows and 6 variables:
- failtime
relapse-free survival (RFS) times (in months)
- failind
relapse indicator, 0 = right censored, 1 = relapse
- treatment
treatment indicator, 0 = GMK, 1 = GMK and IFN
- sex
gender indicator, 0 = male, 1 = female
- age
patient age in years
- perform
ECOG performance status indicator, 0 = fully active patient, able to carry on all pre-disease performance without restriction, 1 = restricted in physically strenuous activity, but are ambulatory and able to carry out work of a light or sedentary nature
References
Kirkwood, J. M., Ibrahim, J., Lawson, D. H., Atkins, M. B., Agarwala, S. S., Collins, K., Mascari, R., Morrissey, D. M., and Chapman, P. B. (2001). High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: Results of the multicenter eastern cooperative oncology group phase II trial E2696. Journal of Clinical Oncology, 19(5), 1430–1436.
R Package Documentation
Browse R Packages
We want your feedback!
Note that we can't provide technical support on individual packages. You should contact the package authors for that.
Embedding an R snippet on your website
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.